Summary
The pharmacokinetics of methimazole following therapeutic doses were studied in healthy subjects, in thyrotoxic and hypothyroid patients before and after treatment to euthyroidism, and in patients with renal or hepatic insufficiency, using a highly sensitive gas chromatographic-mass spectrometric assay. Following intravenous administration of 10mg to healthy subjects, methimazole had an initial distribution half-life (t1/2a of 0.10 to 0.23 hours and an elimination half-life (t1/2b) of 4.9 to 5.7 hours. The absolute bioavailability after oral administration of 10mg methimazole in the fasting state was high, with a mean of 93%.
The pharmacokinetic profiles showed small interindividual variations, although one of the hypothyroid patients had a rapid elimination half-life, in both the hypothyroid arid euthyroid state (2.6 and 2.4 hours, respectively). The elimination rate was not enhanced in the thyrotoxic patients but was slightly prolonged in the hypothyroid patients. There was no influence of renal insufficiency, but a prolonged elimination half-life was observed in patients with hepatic failure, the prolongation being proportional to the degree of impairment.
Thus, the pharmacokinetics of methimazole are relatively simple with small interindividual variations. In general, there are no pharmacokinetic reasons to adjust dosage in the treatment of thyrotoxicosis, except in the rare case of concomitant advanced hepatic insufficiency.
Similar content being viewed by others
References
Alexander, W.E.; Evans, V.; MacAulay, A.; Gallagher, T.F. and Londono, J.: Metabolism of 35S-labelled antithyroid drugs in man. British Medical Journal 2: 290–291 (1969).
Astwood, E.B. and VanderLaan, W.P.: Treatment of hyperthy roidism with propylthiouracil. Annals of Internal Medicine 25: 813–821 (1946).
Baltzer, J.; Lartz, H.G. and Van Zwieten, P.A.: Serum Spiegel und Urinausscheidung von 14C-thiamazol bei Patienten mit Schilddrüsenüberfunction. Deutsche Medizinische Wochenschrift 100: 548–552 (1975).
Cooper, D.S.; Bode, H.H.; Nath, B.; Saxe, V.; Maloof, F. and Ridgway, E.C.: Methimazole pharmacology in man: Studies using a newly developed radioimmunoassay for methimazole. Journal of Clinical Endocrinology and Metabolism 58: 473–479 (1984).
Crooks, J.; Hedley, A.J.; McNee, C. and Stevenson, I.H.: Changes in drug metabolizing ability in thyroid disease. British Journal of Pharmacology 49: 156P–157P (1973).
Dahlberg, P.A.; Karlsson, F.A.; Lindström, B. and Wide, L.: Studies of thyroid hormone and methimazole levels in patients with Graves’ disease on a standardized drug regimen. Clinical Endocrinology 14: 555–562 (1981).
Floberg, S.; Lanbeck, K. and Lindström, B.: Determination of methimazole in plasma using gas chromatography-mass spectrometry after extractive alkylation. Journal of Chromatography 182: 63–70 (1980).
Gomeni, C and Gomeni, R.: IGPHARM: Interactive graphic package for pharmacokinetic analysis. Computers and Biomedical Research 11: 345–361 (1978).
Hallengren, B.; Nilsson, O.R.; Karlberg, B.E.; Melander, A.; Tegler, L. and Wåhlin-Boll, E.: Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. European Journal of Clinical Pharmacology 21: 379–384 (1982).
Jansson, R.; Dahlberg, P.A. and Lindstrom, B.: Comparative bioavailability of Carbimazole and methimazole. International Journal of Clinical Pharmacology, Therapy and Toxicology 21: 505–510 (1983a).
Jansson, R.; Dahlberg, P.A.; Johansson, H. and Lindström, B.: Intrathyroidal concentrations of methimazole in patients with Graves’ disease. Journal of Clinical Endocrinology and Metabolism 57: 129–132 (1983b).
Johansen, K.; Nyboe Andersen, A.; Kampmann, J.P.; Molholm Hansen, J.E. and Mortensen, H.B.: Excretion of methimazole in human milk. European Journal of Clinical Pharmacology 23: 339–341 (1982).
Kampmann, J.P. and Mølholm Hansen, J.: Clinical pharmacokinetics of antithyroid drugs. Clinical Pharmacokinetics 4: 401–428 (1981).
Lawson, A.C.; Rimington, A.C. and Searle, C.E.: Antithyroid activity of 2-carbethoxythio-1-methylglyoxaline. Lancet 2: 619–621 (1951).
Lennard, N.S.; Silas, J.H.; Smith, A.J. and Tucker, G.T.: Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame ionisation and nitrogen selective detection. Journal of Chromatography 133: 161–166 (1977).
Marchant, B.; Lees, J.F.H. and Alexander, W.D.: Antithyroid drugs. Pharmacology and Therapeutics 3: 305–348 (1978).
Melander, A.; Hallengren, B.; Rosendal-Helgesen, S.; Sjøberg, A.K. and Wählin-Boll, E.: Comparative in vitro effects and in vivo kinetics of antithyroid drugs. European Journal of Clinical Pharmacology 17: 295–299 (1980).
Melander, A.; Wåhlin, E.; Danielsson, K. and Hanson, A.: Bioavailability of propylthiouracil: Interindividual variation and influence of food intake. Acta Medica Scandinavica 201: 41–44 (1977).
Nebert, D.W.: Possible clinical importance of genetic differences in drug metabolism. British Medical Journal 283: 537–542 (1981).
Pittman, J.A.; Beschi, R.J. and Smitherman, T.C.: Methimazole: Its absorption and excretion in man and tissue distribution in rats. Journal of Clinical Endocrinology 33: 182–185 (1971).
Skellern, G.G.; Knight, B.I.; Low, C.K.L.; Alexander, W.D.; McLarty, D.G. and Kalk, W.J.: The pharmacokinetics of methimazole after oral administration of Carbimazole and methimazole in hyperthyroid patients. British Journal of Clinical Pharmacology 9: 137–143 (1980).
Skellern, G.G.; Stenlake, J.B.; Williams, W.D. and McLarty, D.G.: Plasma concentrations of methimazole, a metabolite of Carbimazole, in hyperthyroid patients. British Journal of Clinical Pharmacology 1: 265–269 (1974).
Stanley, M.M. and Astwood, E.B.: 1-Methyl-2-mercaptoimidazole: An antithyroid compound highly active in man. Endocrinology 44: 588–589 (1949).
Vesell, E.S.; Shapiro, J.R.; Passananti, G.T.; Jorgensen, H. and Shively, C.A.: Altered plasma half-lives of antipyrine, propylthiouracil and methimazole in thyroid dysfunction. Clinical Pharmacology and Therapeutics 17: 48–56 (1975).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jansson, R., Lindström, B. & Dahlberg, P.A. Pharmacokinetic Properties and Bioavailability of Methimazole. Clin Pharmacokinet 10, 443–450 (1985). https://doi.org/10.2165/00003088-198510050-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198510050-00006